Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01388842 : Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide as Adjunctive Treatment for Cerebral Malaria in Children
PhasePhase 2
AgesMin: 2 Months Max: 12 Years
Inclusion Criteria:

- Age between 2 months and 12 years.

- With malaria infection confirmed by a malaria antigen test and/or a positive blood
smear examination

- AND sustained coma: achieving a Blantyre Coma Score less than 3 for 2, or more, hours
after ruling out and treating hypoglycemia (blood glucose less than 2.2 mmol/l),
ruling out meningitis, and ruling out and treating active clinical seizures.

Exclusion Criteria:

- Refusal to participate

- Other cause of coma (toxic or pre-existing severe neurological disease)

- Terminal respiratory failure (due to brainstem coning)

- Coagulopathic

- Clinically unstable enough to preclude venipuncture and phlebotomy

- Severe malnutrition defined by edema or a weight-for-height minus 3 SD;

- Evidence of pre-existing brain injury

- Advanced AIDS defined by WHO clinical staging 4;
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557